Heart drug developer Kardigan targets $1.4 billion valuation in US IPO
By Prakhar Srivastava June 11 (Reuters) - Clinical-stage biotech Kardigan is targeting a valuation of up to $1.4 billion in its initial public offering in the United States, it said on Thursday, as the company seeks funding to advance the development of three late-stage cardiovascular drug 
